Athira pharma presents preclinical data highlighting fosgonimeton's neuroprotective effects against amyloid-Β-induced pathological alterations and neuroinflammation in models of alzheimer's disease

Bothell, wash., nov. 15, 2023 (globe newswire) -- athira pharma, inc. (nasdaq: atha), a late clinical-stage biopharmaceutical company focused on developing small molecules to restore neuronal health and slow neurodegeneration, presented new preclinical data supporting the potential therapeutic benefit of fosgonimeton for the treatment of alzheimer's disease (ad) and other neurodegenerative diseases at the society for neuroscience (sfn) annual meeting 2023, being held in washington, d.c.
ATHA Ratings Summary
ATHA Quant Ranking